Diagnostic Medical Systems S.A. designs, develops, manufactures, and sells medical imaging systems in France. The company offers ADAM, a software suite for imaging experts; R and F solutions, including Platinum Neo, Platinum Flex, and Optima; bone densitometers, including Stratos and Medix Series; MISTRAL, a manual chest and bone solution; and Camargue series which offers motorized radiographic systems to perform all types of bone and chest exams, including full spine and long leg exams. It also provides mobiles under the !M1, ONYX, Rafale/Rafale DR, and !Mobile Wall Stand names; c-arm products under the EVO R+ FP ADAM and EVO + / EVO R+ names; retrofit kits; and mammography equipment. The company was founded in 1979 and is headquartered in Gallargues-le-Montueux, France.…
Graphique des rendements saisonniers Diagnostic Medical Systems S.A. (DMS1.F)
Diagnostic Medical Systems (EPA: ALDMS) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 136 employees.
The shares were at 0.8920 EUR on 20 November 2026, down 29.5% over 52 weeks. Its 52-week range is 0.8200 EUR to 1.485 EUR: the price is 39.9% below the high and 8.8% above the low.
At a market capitalisation of 23.11M EUR, it trades at 44.6 times trailing earnings and 9.9 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a premium of 75% for ALDMS.
Diagnostic Medical Systems reports return on equity of -0.9%, an operating margin of 3.8% and revenue down 5.8% year over year.
Its debt exceeds its cash by 14.99M EUR, a debt-to-equity ratio of 0.98. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 2.000 EUR is 124.2% above the current price.
No upcoming events tracked.